Gold X2 Mining Inc. (TSXV: AUXX) (OTCQB: GSHRF) (FSE: DF8) (“Gold X2” or the “Company”) is pleased to announce a significant update ...

After 24 months, 34% of veterans who have heart and blood vessel disease and high cholesterol in a quality improvement program that included health care coaches and other resources had improved ...

Minute Audio Program Enters Brainwave Entrainment Sector Amid Surging Consumer Interest in Non-Invasive Focus Enhancement Solutions ...

Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with Prader- ...

-- 63% complete response (CR) rate at any time (n=62); -- 56% CR rate at 3 months (n=62); -- 62% CR rate at 6 months (n=37), with 4 patients having successfully converted to CR post reinduction; and - ...

Broadcast Retirement Network's Jeffrey Snyder discusses how to prevent cardiovascular disease at any age with Cone Health's ...

Discover Telos Corporation's Q3 2025 earnings: record revenue growth, Xacta.ai launch, and raised outlook for 2026.

Topline results that were recently released from Sydnexis’s phase 3 Study of Atropine for the Reduction of Myopia Progression ...

The LRSD board has to start paying attention to spending. If you look at projected student enrollment declines, we cannot ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that KYGEVVI® has been granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults and ...

American Critical Minerals has voluntarily filed a National Instrument 43-101 Technical Report supporting the exploration targets for Potash, Lithium and Bromine. 2.1 billion cubic meters (brine ...